CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 811 enrolled
Drug / intervention
Rivaroxaban +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02744092
NCT02744092N/ACompleted
CompareCT.gov

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

Alliance Foundation Trials, LLC.·interventional·Posted Apr 20, 2016·Updated Oct 3, 2023

In Brief

A clinical study evaluating Rivaroxaban, Apixaban, and 6 other interventions for Cancer and 4 related conditions. Completed, enrolled 811 participants across 151 sites.

Detailed Summary

The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
CountriesUnited States
CollaboratorsPatient-Centered Outcomes Research Institute

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 20, 2016
Enrollment StartDec 13, 2016
Primary CompletionOct 31, 2020
Study CompletionFeb 22, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.2 years ago

Interventions

Rivaroxabandrug

Anticoagulation therapy.

Apixabandrug

Anticoagulation therapy.

Edoxabandrug

Anticoagulation therapy.

Dabigatrandrug

Anticoagulation therapy.

Warfarindrug

Anticoagulation therapy.

Dalteparindrug

Anticoagulation therapy.

Enoxaparindrug

Anticoagulation therapy.

Fondaparinuxdrug

Anticoagulation therapy.